Lukas Frontzkowski

Lukas Frontzkowski

Auto-generated profile, based on publicly available information

Lukas Frontzkowski

Institute for Stroke and Dementia Research (ISD) LMU University Hospital, Ludwig‐Maximilians‐University (LMU) Munich Munich Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
NFNicolai Franzmeier
Nicolai Franzmeier
ADAnna Dewenter
Anna Dewenter
LFLukas Frontzkowski
Lukas Frontzkowski
MDMartin Dichgans
Martin Dichgans
ARAnna Rubinski
Anna Rubinski
MEMichael Ewers
Michael Ewers
In Alzheimer’s disease, PET-assessed tau pathology emerges locally and spreads throughout functionally connected regions.

1 June 2021 in Neurobiology of Aging
Verified
Journal Article
Closed access
ARAnna Rubinski
Anna Rubinski
DTDuygu Tosun
Duygu Tosun
NFNicolai Franzmeier
Nicolai Franzmeier
JNJulia Neitzel
Julia Neitzel
LFLukas Frontzkowski
Lukas Frontzkowski
MEMichael Ewers
Michael Ewers

12 September 2025 in Brain
Verified
Journal Article
Closed access
JPJulia Pescoller
Julia Pescoller
ADAnna Dewenter
Anna Dewenter
ADAmir Dehsarvi
Amir Dehsarvi
ASAnna Steward
Anna Steward
LFLukas Frontzkowski
Lukas Frontzkowski
NFNicolai Franzmeier
Nicolai Franzmeier
In Alzheimer’s disease (AD), fibrillar tau pathology is a key driver of neurodegeneration and cortical atrophy. Yet, emerging evidence suggests that tau aggregates also contribute to white matter (WM) damage. Specifically, physiological tau stabilizes intra-axonal microtubules, whereas hyperphosphorylated tau disrupts microtubule integrity, with ensuing intraneuronal tau aggregation, neuronal disconnection and axonal degeneration. Therefore, we investigated whether cortical tau promotes atrophy in connected WM regions in AD. To this end, we included 186 amyloid-positive (Aβ+) patients across the AD spectrum and 102 cognitively normal (CN) amyloid-negative (Aβ−) participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) with baseline amyloid-PET, tau-PET and T1-weighted MRI. Longitudinal tau-PET and MRI (∼2 years) were available for a subset of 138 participants to assess the relationship between tau accumulation and WM atrophy over time. For replication, we included 378/60 CN Aβ+/Aβ− participants from the A4/LEARN cohort with baseline amyloid-PET, tau-PET and T1-weighted MRI, where a subset of 141/4 CN Aβ+/Aβ− subjects had ∼5-year longitudinal tau-PET and MRI. Cortical tau-PET standardized uptake value ratios were extracted from 210 cortical regions of the Brainnetome Atlas. In addition, we used a diffusion MRI-based tractography template to determine WM volumes of fibre tracts connected to cortical regions using segmented T1-weighted MRI. Using linear regression, we tested whether higher cortical tau-PET at baseline was associated with (i) lower baseline WM volume and (ii) faster WM volume loss over time, and (iii) whether faster longitudinal tau-PET increases paralleled faster WM loss. Testing the reverse model examined whether baseline WM atrophy predicted faster subsequent tau-PET increase in connected regions. Models were adjusted for age, sex, intracranial volume, WM hyperintensity volume, ApoE4 status and global amyloid-PET. In ADNI participants, elevated baseline cortical tau-PET in temporal regions was associated with lower baseline WM volume in adjacent regions, with more pronounced effects in patients across the AD spectrum and with weaker associations in the preclinical A4/LEARN sample. In both samples, higher baseline temporo-parietal tau-PET and faster tau-PET increase over time were significantly linked to accelerated volume loss in connected WM regions, which was especially pronounced in individuals on the AD spectrum. Importantly, baseline WM volume did not predict subsequent tau-PET rates of change in adjacent cortical regions, suggesting a unidirectional relationship between fibrillar tau and subsequent WM degeneration. Together, our findings suggest that cortical tau accumulation promotes atrophy in adjacent WM regions in AD, highlighting that tau-induced axonal degeneration and, potentially, neuronal disconnection might play a pivotal role in disease progression.

10 June 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
LFLukas Frontzkowski
Lukas Frontzkowski
JGJohannes Gnörich
Johannes Gnörich
MGMattes Gross
Mattes Gross
ADAmir Dehsarvi
Amir Dehsarvi
SRSebastian N. Roemer-Cassiano
Sebastian N. Roemer-Cassiano
NFNicolai Franzmeier
Nicolai Franzmeier
Purpose: Progressive supranuclear palsy (PSP) is a fatal 4-repeat (4R) tauopathy with progressive movement phenotypes. In-vivo 4R tau biomarkers are therefore crucial for PSP diagnosis, monitoring, and treatment evaluation. The tau-PET tracer [ 18 F]PI-2620 binds to 4R tau and shows increased uptake in PSP-associated regions (e.g., globus pallidus), and is therefore a candidate 4R tau biomarker. However, commonly used cerebellar tau-PET reference regions show regional proximity to cerebellar 4R tau deposits in PSP, confounding semiquantitative [ 18 F]PI-2620 assessments. Therefore, we employed bias-free image-derived input function (IDIF) PET quantification to identify an optimized data-driven reference region for assessing 4R tau in PSP. Methods: Dynamic [ 18 F]PI-2620 PET (60 min) was acquired in 58 PSP-Richardson Syndrome (PSP-RS) and 18 healthy controls (HC). IDIF-modelling with carotid timeseries derived total distribution volume (VT). Iteratively normalizing VT images to atlas-based white matter (WM), we identified reference candidates maximizing PSP-RS vs. HC pallidum differences. The best-performing WM references were combined to a temporo-orbital WM reference, validated in PSP-nonRS ( n = 54), HC ( n = 18), and disease controls (α-synucleinopathies, n = 21; Alzheimer’s disease (AD, n = 22) using VT-ratios (VTr) and 20-40min static standardized uptake value ratios (SUVr). Results: Using the data-driven temporo-orbital WM reference, PSP patients showed significantly higher basal ganglia [ 18 F]PI-2620 signal vs. HC compared to cerebellar normalization. Receiver operating curve (ROC) analysis confirmed higher diagnostic accuracy using the temporo-orbital WM reference. Pallidum [ 18 F]PI-2620 showed significant associations with clinical disease severity exclusively when using the novel temporo-orbital WM reference. Conclusions: A data-driven temporo-orbital WM reference optimizes [ 18 F]PI-2620 PET assessment for PSP diagnosis, outperforming conventional cerebellar references used in tau-PET imaging.

18 December 2025 in Brain
Verified
Journal Article
Closed access
ASAnna Steward
Anna Steward
ADAnna Dewenter
Anna Dewenter
FHFabian Hirsch
Fabian Hirsch
SRSebastian N Roemer-Cassiano
Sebastian N Roemer-Cassiano
ZZZeyu Zhu
Zeyu Zhu
NFNicolai Franzmeier
Nicolai Franzmeier
In Alzheimer’s disease, carriage of the apolipoprotein E ε4 (ApoE4) risk allele is linked to faster tau accumulation at lower amyloid-PET levels, thereby accelerating disease progression. However, it remains unclear whether this ApoE4-facilitated transition from amyloidosis to tauopathy is mechanistically promoted by increased secretion of phosphorylated tau (ptau), a key intermediate that drives the amyloid-to-tauopathy transition, or alternatively by increased ptau-driven tau aggregation. Therefore, we investigated where along the amyloid-to-tau axis ApoE4 accelerates tau aggregation and assessed: (i) whether ApoE4 increases ptau secretion; or (ii) whether ApoE4 increases ptau-associated tau aggregation. To this end, we analysed two large-scale APOE-genotyped cohorts covering the full Alzheimer’s disease spectrum (Alzheimer’s Disease Neuroimaging Initiative; ADNI: n = 201) as well as a preclinical cohort (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration study; A4-LEARN: n = 200), integrating baseline amyloid-PET, plasma ptau217 and CSF ptau181 with longitudinal tau-PET. Using linear regression, we tested whether ApoE4 carriage moderates: (i) amyloid-PET-associated plasma ptau217 increases; or (ii) ptau217-associated tau spreading from local epicentres across patient-tailored tau spreading stages. All analyses were independently validated across both cohorts, including an additional replication in an ADNI subset (n = 115) with available CSF ptau181 measures as an alternative marker of ptau secretion. Finally, we used logistic regression to determine ApoE4 allele count-stratified plasma ptau217 thresholds marking early pathological tau-PET increases. We found that ApoE4 did not facilitate amyloid-PET-associated ptau increases, suggesting that amyloid-related ptau secretion is not altered by ApoE4 carriage. Contrastingly, we found that plasma ptau217 elevations were linked to faster tau-PET spread from local epicentres across connected brain regions in an ApoE4 allele dose-dependent manner, independent of amyloid [ADNI/A4-LEARN: mean standardized beta (β) = 0.44/0.56, P < 0.001/P < 0.001]. Lastly, we found that a higher ApoE4 allele count was linked to lower ptau217 thresholds marking transition to tauopathy, i.e. early abnormal tau-PET increases, consistently across both samples (ADNI: 0/1/2 ApoE4 alleles = 0.62/0.34/0.15 pg/ml, representing ∼45% and ∼76% reductions from non-carriers; Fujirebio ptau217 assay; A4-LEARN: 0/1/2 ApoE4 alleles = 0.31/0.23/0.18 pg/ml, representing ∼26% and ∼42% reductions; Eli Lilly ptau217 assay). These findings suggest that ApoE4, i.e. the key genetic risk factor for sporadic Alzheimer’s disease, facilitates amyloid-dependent tau aggregation in an allele dose-dependent manner by enhancing the ptau-driven spread of fibrillar tau, leading to an earlier transition from amyloidosis to tauopathy at lower ptau217 levels. This has implications for plasma ptau-based screening approaches and therapeutic timing of anti-amyloid drugs in ApoE4 carriers. Specifically, ApoE4 carriers may require genotype-adjusted ptau thresholds to detect Alzheimer’s disease pathophysiology, as well as anti-amyloid treatment at lower ptau levels to prevent the transition to tauopathy, which ultimately drives neurodegeneration and cognitive decline.

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
LFLukas Frontzkowski
Lukas Frontzkowski
NFNicolai Franzmeier
Nicolai Franzmeier
JNJulia Neitzel
Julia Neitzel
YLYing Luan
Ying Luan
CHChristian Habeck
Christian Habeck
MEMichael Ewers
Michael Ewers